Novavax have announced an agreement for the development and commercialization of Novavax’ COVID‑19 vaccine candidate in India and other low- and middle-income countries.
The agreement is expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries, Novavax said.“We believe that Novavax’ NVX-CoV2373 has significant potential to successfully prevent COVID-19.
Given our experience with Novavax on the development of a malaria vaccine, we know the power of their vaccine technologies," said Adar Poonawalla, Chief Executive Officer of Serum Institute of India. “We will work urgently together to bring this vaccine to patients in these geographies."This agreement excludes major upper-middle and.